1. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling
- Author
-
Peter Carmeliet, Isabelle Margaill, Fabian Docagne, Olivier Nicole, Carine Ali, Denis Vivien, Alain Buisson, and Eric T. MacKenzie
- Subjects
Biology ,Pharmacology ,Tissue plasminogen activator ,Receptors, N-Methyl-D-Aspartate ,General Biochemistry, Genetics and Molecular Biology ,Membrane Potentials ,Glutamatergic ,Neuroserpin ,In vivo ,medicine ,Animals ,Receptor ,Neurons ,Ion Transport ,Cell Death ,Activator (genetics) ,Hydrolysis ,General Medicine ,nervous system ,Biochemistry ,Tissue Plasminogen Activator ,NMDA receptor ,Calcium ,Signal transduction ,medicine.drug ,Signal Transduction - Abstract
Tissue-plasminogen activator (t-PA) is now available for the treatment of thrombo-embolic stroke but adverse effects have been reported in some patients, particularly hemorrhaging. In contrast, the results of animal studies have indicated that t-PA could increase neuronal damage after focal cerebral ischemia. Here we report for the first time that t-PA potentiates signaling mediated by glutamatergic receptors by modifying the properties of the N-methyl-D-aspartate (NMDA) receptor. When depolarized, cortical neurons release bio-active t-PA that interacts with and cleaves the NR1 subunit of the NMDA receptor. Moreover, the treatment with recombinant t-PA leads to a 37% increase in NMDA-stimulated fura-2 fluorescence, which may reflect an increased NMDA-receptor function. These results were confirmed in vivo by the intrastriatal injection of recombinant-PA, which potentiated the excitotoxic lesions induced by NMDA. These data provide insight into the regulation of NMDA-receptor-mediated signaling and could initiate therapeutic strategies to improve the efficacy of t-PA treatment in man.
- Published
- 2001